Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15286031 | 1.00 | CA1 (0.36) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL14228751 | 0.81 | CA1 (0.33) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL14229576 | 0.77 | CCR6 (0.40) | KMT2A | |
| SCHEMBL6902606 | 0.75 | CA1 (0.51) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL6907617 | 0.75 | CA1 (0.51) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL5873450 | 0.75 | CA1 (0.51) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL16590754 | 0.75 | NLRP3 (0.33) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL16583762 | 0.75 | FBP1 (0.31) | CA1CA2CA4CA6 | |
| SCHEMBL16583761 | 0.74 | CA1 (0.30) | CA1CA2CA4CA6 | |
| SCHEMBL13766051 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CA1 3117/4885CA2 3367/4885CA4 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.